Qvents
Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Home
About Us
Contact Us
Expert Panel
Tags
Qvents
Warning Letters
483s
Recalls
Import Alerts
Quality Insights
Tags
Forums
Learning Resources
Upcoming Trainings
Training Archives
Guidelines
Pharma Jobs
Job Openings
Post a Job
Jobs posted by me
Users & Profiles
News
Login/Register
Individual
Company
Home
About Us
Contact Us
Expert Panel
Tags
Qvents
Warning Letters
483s
Recalls
Import Alerts
Quality Insights
Tags
Forums
Learning Resources
Upcoming Trainings
Training Archives
Guidelines
Pharma Jobs
Job Openings
Post a Job
Jobs posted by me
Users & Profiles
News
Login/Register
Archives:
News
Laurus Labs receives in-principle approv
Qvents
May 4, 2023
Teva USA is recalling thirteen lots of F
Qvents
April 30, 2023
Sun Pharma, Halol is recalling one lot o
Qvents Team
April 30, 2023
Akorn USA Issues recall of various Human
Qvents
April 29, 2023
Sun Pharma has received a USFDA Consent
Qvents
April 28, 2023
USFDAÂ had declined to approve Eli Lill
Qvents
April 18, 2023
FDA Announce Decision to Withdraw Approv
Qvents Team
April 18, 2023
FDA issues draft Guidance on Notifying F
Qvents Team
April 9, 2023
Pharming
Qvents Team
April 9, 2023
USFDA inspected Global Pharma facility f
” target=”_blank”>Read More..</a>
Qvents Team
March 31, 2023
1
…
26
27
28
Facebook
LinkedIn
Twitter
Search Posts
Latest Posts
Dabur Facility Placed Under Import Alert
June 15, 2026
USFDA Warning letter to Intas Flags Integrity of Electronic Records, Method Validations, OOS investigations
May 22, 2026
Qvents Apps and Tools For QMS and GMP Processes
April 22, 2026
USFDA Issues Guidance for Impurity Specifications for Semi-Synthetic & Fermentation Antibiotics
April 21, 2026
Responding to FDA Form 483: USFDA Issues Guidance
April 2, 2026